Century Therapeutics’ (IPSC) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Century Therapeutics (NASDAQ:IPSC) in a research report report published on Wednesday morning,Benzinga reports. They currently have a $5.00 target price on the stock.

A number of other research analysts also recently weighed in on IPSC. Piper Sandler decreased their price target on Century Therapeutics from $12.00 to $4.00 and set an “overweight” rating for the company in a research note on Monday, December 30th. Chardan Capital lowered their target price on shares of Century Therapeutics from $17.00 to $11.00 and set a “buy” rating on the stock in a report on Thursday, November 7th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, Century Therapeutics has a consensus rating of “Buy” and a consensus price target of $10.00.

Century Therapeutics Stock Down 0.7 %

NASDAQ IPSC opened at $0.89 on Wednesday. The firm’s 50 day moving average is $1.18 and its 200-day moving average is $1.56. The company has a market capitalization of $75.76 million, a PE ratio of -0.48 and a beta of 1.76. Century Therapeutics has a 12-month low of $0.87 and a 12-month high of $5.51.

Century Therapeutics (NASDAQ:IPSC) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.08. Century Therapeutics had a negative net margin of 4,837.73% and a negative return on equity of 61.66%. The firm had revenue of $0.79 million for the quarter, compared to analysts’ expectations of $0.47 million. During the same period in the previous year, the firm posted ($0.55) EPS. As a group, sell-side analysts expect that Century Therapeutics will post -1.63 EPS for the current year.

Institutional Investors Weigh In On Century Therapeutics

Large investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC increased its holdings in shares of Century Therapeutics by 3.5% in the third quarter. Geode Capital Management LLC now owns 968,182 shares of the company’s stock valued at $1,656,000 after purchasing an additional 32,614 shares during the last quarter. State Street Corp raised its holdings in Century Therapeutics by 7.4% in the 3rd quarter. State Street Corp now owns 836,914 shares of the company’s stock valued at $1,431,000 after acquiring an additional 57,323 shares during the period. Wellington Management Group LLP acquired a new stake in Century Therapeutics during the third quarter worth approximately $284,000. Renaissance Technologies LLC boosted its holdings in shares of Century Therapeutics by 6.1% during the second quarter. Renaissance Technologies LLC now owns 165,500 shares of the company’s stock worth $422,000 after acquiring an additional 9,500 shares during the period. Finally, Bank of New York Mellon Corp grew its position in shares of Century Therapeutics by 110.1% in the second quarter. Bank of New York Mellon Corp now owns 149,000 shares of the company’s stock valued at $380,000 after purchasing an additional 78,088 shares during the last quarter. Institutional investors own 50.20% of the company’s stock.

Century Therapeutics Company Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.